ANNUAL REPORT
Download the full report, individual sections or visit iXBRL viewer
We are a focused biopharma company with strong momentum and big ambitions
2023 performance and key performance indicators
Financial performance
We delivered strong performance and upgraded our growth outlooks. Broad-based performance drove sales, profits and earnings growth.
Research and development
We continued to strengthen the late-stage pipeline with organic R&D delivery and targeted business development, supporting future growth.
Responsible business
We continue to be recognised for our environmental and sustainability leadership. Our ESG Performance Rating is on track based on 95% of all performance metrics being met or exceeded. The metrics cover our six focus areas: access to healthcare, global health and health security, environment, diversity, equity and inclusion, ethical standards, and product governance.
Our culture and people
Our purpose – to unite science, technology and talent to get Ahead of disease Together – puts our people at the heart of our success.
We are committed to making GSK a place where people can thrive, with a culture where we are all ambitious for patients, accountable for impact, and do the right thing. This means we support our people to do things better and faster, focusing on what matters most.
Culture progress is measured through our employee surveys.
Our employee engagement score remained high at 81% in 2023.
Our business model
We unite science, technology and talent to get ahead of disease together for health impact, shareholder returns and thriving people.
Experts in science, technology, manufacturing, regulation, intellectual property and commercialisation
70,200
GSK people
>75
countries worldwide
22,000
suppliers working directly with GSK
£6.2bn
R&D investment in 2023 – up 13% AER, 14% CER
37
manufacturing sites
4
global R&D centres in the US, UK, Belgium and Italy
Vaccines
Our broad vaccines portfolio targets infectious diseases at every stage of life, helping to protect people from meningitis, shingles, RSV, flu, polio and many more.
Specialty Medicines
Our specialty medicines prevent and treat diseases, from HIV and respiratory diseases, to immune-inflammation diseases like lupus, to cancer. Many are first or best-in-class.
General Medicines
We have a portfolio of more than 150 primary care medicines, including our inhaled medicines for asthma and COPD, and antibiotics for infections.
Infectious diseases
Our infectious diseases portfolio is the broadest in the industry and, including HIV, accounts for two thirds of our pipeline.
HIV
We are leaders in HIV, focused on ending the global epidemic. We have an industry-leading pipeline, driven by patient insights.
Respiratory/immunology
We’re pushing the frontiers of respiratory science and harnessing the science of the immune system to transform patient outcomes in areas of unmet need,
based on decades of innovative research.
Oncology
We have an emerging portfolio focused on blood and women's cancers, and are seeking to make transformative breakthroughs in immuno-oncology.
Pipeline
We are leveraging new platform and data technology at every step of the R&D process to be faster, more effective, and more predictive in discovering and developing innovative new medicines and vaccines.
Performance
We use technology to enable more productive and efficient manufacturing processes, supply chain reliability and returns on investment.
People and productivity
Technology is also core to how we work. We ensure our people have the tools, analytical capabilities and resources to make data-driven decisions and do their best work.
Innovation
We develop and launch new medicines and vaccines where they are needed, with better and faster R&D.
Performance
Our bold ambitions for patients are reflected in our upgraded growth outlooks to 2026 and 2031.
Trust
We focus on issues where we can have the greatest impact and reduce pressure on health systems including tackling health challenges and inequities, protecting the environment and taking action on diversity, equity and inclusion.
Patients
2.3bn packs of medicines and doses of vaccines delivered
Shareholders
58p per share dividend
Society
£1.3bn corporate income tax paid; in addition we pay duties, levies, transactional and employment taxes
The economy
Disease prevention and earlier intervention to improve health can lessen pressure on health systems and support economic productivity.
Our people
We support all our people to grow, be well and do work that really matters.
Reinvestment
The returns we make enable us to reinvest in discovering and developing new vaccines and medicines so we can continue getting ahead of disease.
